MAR 24, 2020 5:51 AM PDT

Ultra sensitive cancer diagnostic detects DNA "fingerprints" in liquid biopsies

WRITTEN BY: Tara Fernandez

Researchers from the Broad and Dana-Farber Cancer Institutes have developed a diagnostic technology that can be used to monitor patients for the presence of recurring cancer cells after receiving treatment. This “liquid biopsy” screening platform is so sensitive, that it can detect metastatic cancer cells years before they would show up using traditional techniques.

The retrospective study, published in Clinical Cancer Research, tracked banked blood samples from breast cancer patients in the years following their initial diagnosis and treatment. Nearly 30 percent of women diagnosed with breast cancer will develop metastatic disease, as a result of cancer cells breaking away from the original tumor in the breast and migrating to other parts of the body through the bloodstream or the lymphatic system.

Senior author Viktor Adalsteinsson and his team first used whole-exome DNA sequencing to identify the unique DNA “fingerprint” from the tumors isolated from each of the 142 patients in the study. Significantly, the researchers found trace amounts of these cancer DNA sequences in the patients’ blood samples up to three years before metastatic cancer recurrence was picked up using standard diagnostic approaches.

“By taking an individualized approach — searching for many mutations that are specific to one patient’s cancer — we could greatly increase our sensitivity to detect traces of cancer DNA in patients who had completed their initial treatment plan,” explained Adalsteinsson.

“And with that sensitivity, we could identify residual cancer from blood samples taken many months to years before a recurring case was diagnosed through standard approaches.”

Future studies are going to employ whole-genome sequencing to boost the test’s sensitivity by collecting more genetic information about the patient’s tumor. In whole-genome sequencing, large amounts of DNA are sequenced at a single time, allowing researchers to perform a more in-depth characterization of the patient’s entire genome. 

With this technology, cancer patients would be able to receive more timely interventions should their cancer return or residual malignant cells be present after their initial treatment.

According to Adalsteinsson, “When we did detect residual disease in blood, following initial courses of treatment, it was a strong predictor of future recurrence. While this was a retrospective study, if a blood biopsy can give clinicians this early warning in real-time, that might provide the opportunity to alter a patient’s outcome.”

 

 


Source: The Harvard Gazette, Clinical Cancer Research.

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
MAY 24, 2021
Clinical & Molecular DX
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
MAY 24, 2021
Discovery of Viral Peptides Paves the Way for Cheaper, More Accurate COVID Diagnostics
Over 1.5 billion vaccine doses have been administered worldwide, but SARS-CoV-2 variants are now threatening efforts to ...
JUN 02, 2021
Genetics & Genomics
A Genetic Form of ALS is Discovered
JUN 02, 2021
A Genetic Form of ALS is Discovered
Some medical mysteries have become much easier to solve because of advanced genetic techniques that have enabled researc ...
JUN 08, 2021
Neuroscience
Simple Blood Test Can Detect Depression and Underlying Neurodegeneration
JUN 08, 2021
Simple Blood Test Can Detect Depression and Underlying Neurodegeneration
Researchers led by King’s College London have found that levels of a protein known as neurofilament light chain (N ...
SEP 05, 2021
Microbiology
Gut Bacteria May Influence Infant Brain Development
SEP 05, 2021
Gut Bacteria May Influence Infant Brain Development
Our health is closely connected to the community of microbes we carry in our gut. For example, these microbes have a pow ...
SEP 20, 2021
Cancer
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
SEP 20, 2021
An Established Ovarian Cancer Antigen Presents a Promising Therapeutic Target
For the past several decades, cancer antigen 125 (CA 125), a protein located on the surface of ovarian cancer cells, has ...
OCT 14, 2021
Cancer
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
OCT 14, 2021
Mechanism of Resistance to Colorectal Cancer Treatment Uncovered
Colorectal cancer develops when a series of changes occur across multiple genes.  While researchers have paid signi ...
Loading Comments...